Célestine Simand

641 total citations
20 papers, 223 citations indexed

About

Célestine Simand is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Célestine Simand has authored 20 papers receiving a total of 223 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 9 papers in Oncology and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Célestine Simand's work include Acute Myeloid Leukemia Research (7 papers), Acute Lymphoblastic Leukemia research (5 papers) and CAR-T cell therapy research (4 papers). Célestine Simand is often cited by papers focused on Acute Myeloid Leukemia Research (7 papers), Acute Lymphoblastic Leukemia research (5 papers) and CAR-T cell therapy research (4 papers). Célestine Simand collaborates with scholars based in France, United States and Slovakia. Célestine Simand's co-authors include Blandine Guffroy, Yasmine Nivoix, Raoul Herbrecht, Marie‐Pierre Ledoux, Yosr Hicheri, Xavier Thomas, Céline Berthon, Françoise Huguet, Patrice Chevallier and Susan Chan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Célestine Simand

18 papers receiving 223 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Célestine Simand France 8 82 75 72 58 57 20 223
Yuewen Fu China 9 147 1.8× 41 0.5× 43 0.6× 68 1.2× 50 0.9× 40 265
Giulia Tolomelli Italy 8 82 1.0× 36 0.5× 126 1.8× 44 0.8× 135 2.4× 13 299
Chiara Ghiggi Italy 8 87 1.1× 45 0.6× 134 1.9× 65 1.1× 75 1.3× 24 318
Anne‐Claire Mamez Switzerland 10 117 1.4× 29 0.4× 128 1.8× 78 1.3× 153 2.7× 39 353
Sophie Ducastelle France 10 182 2.2× 52 0.7× 45 0.6× 48 0.8× 54 0.9× 43 280
IW Blau Germany 11 149 1.8× 42 0.6× 98 1.4× 97 1.7× 111 1.9× 16 290
Feng‐Ming Tien Taiwan 12 184 2.2× 44 0.6× 51 0.7× 80 1.4× 71 1.2× 27 351
Beki James United Kingdom 8 77 0.9× 34 0.5× 43 0.6× 32 0.6× 27 0.5× 19 161
Angela Passi Italy 8 117 1.4× 15 0.2× 65 0.9× 59 1.0× 38 0.7× 12 200
Masaharu Tamaki Japan 9 98 1.2× 18 0.2× 26 0.4× 50 0.9× 67 1.2× 48 201

Countries citing papers authored by Célestine Simand

Since Specialization
Citations

This map shows the geographic impact of Célestine Simand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Célestine Simand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Célestine Simand more than expected).

Fields of papers citing papers by Célestine Simand

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Célestine Simand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Célestine Simand. The network helps show where Célestine Simand may publish in the future.

Co-authorship network of co-authors of Célestine Simand

This figure shows the co-authorship network connecting the top 25 collaborators of Célestine Simand. A scholar is included among the top collaborators of Célestine Simand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Célestine Simand. Célestine Simand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dieudonné, Yannick, Emmanuel Chatelus, Thierry Martin, et al.. (2025). POS1121 THE USE OF THE CD3/CD19 T CELL ENGAGER BLINATUMOMAB IN SEVERE SYSTEMIC SCLEROSIS: A CASE SERIES. Annals of the Rheumatic Diseases. 84. 1203–1203.
2.
3.
Guffroy, Blandine, Célestine Simand, Karin Bilger, et al.. (2023). Early Autologous Hematopoietic Stem Cells (AHSC) Boost (HCB) to Overcome Immune Effector Cell-Associated Hematotoxicity (ICAHT) after CAR T-Cell Therapy for Lymphoma: A Single Center Experience. Blood. 142(Supplement 1). 6902–6902. 1 indexed citations
4.
Garciaz, Sylvain, Sarah Bertoli, David A. Sallman, et al.. (2023). Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study. Blood. 142(Supplement 1). 161–161. 7 indexed citations
5.
Borgne, Pierrick Le, Maleka Schenck, Jean-Étienne Herbrecht, et al.. (2022). Comparison of Short- and Long-Term Mortality in Patients with or without Cancer Admitted to the ICU for Septic Shock: A Retrospective Observational Study. Cancers. 14(13). 3196–3196. 9 indexed citations
6.
7.
Decroocq, Justine, Sylvain Garciaz, Amine Belhabri, et al.. (2022). Therapy related myeloid neoplasms (t-MNs) following PARP inhibitors (PARPi): Real-life experience.. Journal of Clinical Oncology. 40(16_suppl). 7057–7057. 1 indexed citations
8.
Robin, Marie, Thomas Rémen, Amandine Luc, et al.. (2021). On Behalf of the SFGM-TC: Retrospective Comparison of Reduced and Higher Intensity Conditioning for High-Risk Myelodysplastic Syndrome Treated With Allogeneic Stem-Cell Transplantation. Clinical Lymphoma Myeloma & Leukemia. 22(1). 34–43. 3 indexed citations
9.
Rank, Andreas, Christophe Peczynski, Myriam Labopin, et al.. (2021). Feasibility and Outcomes of a Third Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Transplantation and Cellular Therapy. 27(5). 408.e1–408.e6. 6 indexed citations
10.
Simand, Célestine, Céline Keime, Aurélie Caye, et al.. (2021). Ikaros deficiency is associated with aggressive BCR-ABL1 B-cell precursor acute lymphoblastic leukemia independent of the lineage and developmental origin. Haematologica. 107(1). 316–320. 1 indexed citations
11.
Villard, Odile, et al.. (2021). Unusual presentation of toxoplasmosis with gastro‐intestinal involvement in HLA non‐identical stem cell transplantation. Transplant Infectious Disease. 23(4). 1 indexed citations
12.
Gras, Stéphanie Le, et al.. (2020). Ikaros antagonizes DNA binding by STAT5 in pre-B cells. PLoS ONE. 15(11). e0242211–e0242211. 11 indexed citations
13.
Bories, Pierre, Naïs Prade, Bastien Cabarrou, et al.. (2020). Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine. PLoS ONE. 15(10). e0238795–e0238795. 13 indexed citations
14.
Thomas, Xavier, Emmanuel Raffoux, Françoise Huguet, et al.. (2020). Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Leukemia & lymphoma. 62(3). 620–629. 40 indexed citations
15.
Simand, Célestine, et al.. (2020). Incidental Discovery of a COVID-19 Infection on a Reevaluation FDG PET/CT in a Patient Treated for Hodgkin Lymphoma. Clinical Nuclear Medicine. 45(8). 644–646. 4 indexed citations
16.
Ledoux, Marie‐Pierre, Blandine Guffroy, Yasmine Nivoix, Célestine Simand, & Raoul Herbrecht. (2020). Invasive Pulmonary Aspergillosis. Seminars in Respiratory and Critical Care Medicine. 41(1). 80–98. 78 indexed citations
17.
Thomas, Xavier, Emmanuel Raffoux, Françoise Huguet, et al.. (2019). PS946 BLINATUMOMAB + PONATINIB FOR RELAPSED PH1‐POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: THE FRENCH EXPERIENCE. HemaSphere. 3(S1). 426–427. 2 indexed citations
18.
Mastio, Jérôme, et al.. (2018). Ikaros cooperates with Notch activation and antagonizes TGFβ signaling to promote pDC development. PLoS Genetics. 14(7). e1007485–e1007485. 13 indexed citations
19.
Bories, Pierre, Sébastien Lamy, Célestine Simand, et al.. (2018). Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey. Haematologica. 103(12). 2040–2048. 18 indexed citations
20.
Thomas, Xavier, Françoise Huguet, Céline Berthon, et al.. (2018). Blinatumomab + Ponatinib for Relapsed Ph1-Positive Acute Lymphoblastic Leukemia: The French Experience. Blood. 132(Supplement 1). 4014–4014. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuewen Fu Breakdown of academic impact, for papers by Giulia Tolomelli Breakdown of academic impact, for papers by Chiara Ghiggi Breakdown of academic impact, for papers by Anne‐Claire Mamez Breakdown of academic impact, for papers by Sophie Ducastelle Breakdown of academic impact, for papers by IW Blau Breakdown of academic impact, for papers by Feng‐Ming Tien Breakdown of academic impact, for papers by Beki James Breakdown of academic impact, for papers by Angela Passi Breakdown of academic impact, for papers by Masaharu Tamaki
Rankless by CCL
2026